The Landscape of Immunotherapy for Retroperitoneal Sarcoma DOI Creative Commons
Alicia A. Gingrich, Elise F. Nassif, Christina L. Roland

et al.

Current Oncology, Journal Year: 2023, Volume and Issue: 30(2), P. 2144 - 2158

Published: Feb. 9, 2023

Significant multidisciplinary scientific effort has been undertaken to understand the heterogeneous family of neoplasms that comprise soft tissue sarcomas. Within this neoplasms, outcomes for retroperitoneal sarcomas (RPS) are currently limited given a lack effective therapies. In review, we focus on immunotherapy and its relationship with common RPS histologic subtypes. Although initial patients immune checkpoint inhibition alone have somewhat disappointing, subsequent analyses histologies, tumor microenvironment, sarcoma class, infiltrating lymphocytes genetic analysis mutational burden yielded insight into interplay between immunotherapy. Such approaches all provided critical environment characterization these tumors, targets potential in future clinical trials. With insight, molecularly tailored combination treatments improving response rates oncologic promising.

Language: Английский

Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy DOI Creative Commons

Enkui Zhang,

Chengsheng Ding,

Shuchun Li

et al.

Biomarker Research, Journal Year: 2023, Volume and Issue: 11(1)

Published: March 9, 2023

Abstract Immune checkpoint inhibitors (ICIs) targeting PD-1 or PD-L1 have emerged as a revolutionary treatment strategy for human cancer patients. However, the response rate to ICI therapy varies widely among different types of tumours, we are beginning gain insight into mechanisms well biomarkers therapeutic and resistance. Numerous studies highlighted dominant role cytotoxic T cells in determining ICIs. Empowered by recent technical advances, such single-cell sequencing, tumour-infiltrating B been identified key regulator several solid tumours affecting tumour progression In current review, summarized advances regarding underlying therapy. Some shown that B-cell abundance is positively associated with favourable clinical outcomes, while others indicated they tumour-promoting, implying biological function complex landscape. The molecular involved multiple aspects functions cells, including activation CD8+ secretion antibodies cytokines, facilitation antigen presentation process. addition, other crucial mechanisms, regulatory (Bregs) plasma discussed. Here, summarizing dilemmas studies, depicted landscape cancers paved way future research this field. Graphical

Language: Английский

Citations

58
GENOME-WIDE ANALYSIS OF TRIPLE-NEGATIVE PHENOTYPE BREAST TUMORS DOI Open Access

М.K. Ibragimova,

M.M. Tsyganov,

N.V. Litvyakov

et al.

Cardiometry, Journal Year: 2022, Volume and Issue: 24, P. 58 - 60

Published: Nov. 30, 2022

Identification of the molecular genetic phenotype breast carcinomas is an important prognostic factor disease, and helps to personalize treatment such patients. According evidence data from reference literature, cancer (BC) with a triple negative among all subtypes accounts for about 10-24%, showing most aggressive progression and, as result, has worst prognosis.

Language: Английский

Citations

38
ACCOMPANYING TRANSCRANIAL MAGNETOTHERAPY IN COMBINATION TREATMENT OF HIGH-GRADE GLIAL BRAIN TUMORS DOI Open Access

I.A. Popov,

A.I. Shikhlyarova,

E.M. Frantsiyants

et al.

Cardiometry, Journal Year: 2022, Volume and Issue: 24, P. 56 - 58

Published: Nov. 30, 2022

Low survival and poor quality of life in patients with high-grade brain gliomas (HGG) dictate the need to develop promote new approaches, including accompanying transcranial magnetic therapy (TMT) pulse-type field (PT MF) ultra-low-frequency fields (ULF MF), characterized by their non-invasiveness safety applied procedures. The key point these original wave technologies is construction algorithms actions based on principles activation therapy, which was developed as a result discovery “Pattern development qualitatively differing general nonspecific adaptational reactions organism” (Scientific Discovery Registration Certificate No. 158 issued Committee Inventions Discoveries at Council Ministers USSR, 1975).

Language: Английский

Citations

38
GD2-SPECIFIC CAR-T CELLS CO-EXPRESSING THE IL15 MEMBRANE FORM EFFECTIVELY LYSE GD2-POSITIVE CELL TARGETS DOI Open Access

M.D. Mollaev,

P.N. Vikhreva,

A.V. Kibardin

et al.

Cardiometry, Journal Year: 2022, Volume and Issue: 24, P. 26 - 27

Published: Nov. 30, 2022

Genetically modified T cells expressing chimeric receptors (CAR-T) have become an important tool for the treatment of CD19+ hematological tumors. Due to a single-chain variable fragment antibody as part CAR receptor, acquire their specificity against selected tumorassociated antigens. The 3rd generation also includes transmembrane, co-stimulatory domains, and tyrosine activation motifs derived from CD3z.

Language: Английский

Citations

38
STUDY OF BIOLOGICAL ACTIVITY OF DOXORUBICIN CONJUGATE WITH NACETYL-D-GALACTOSAMINE HYDRASONIC LINKER DOI Open Access

Anna S. Pestretsova,

D.V. Kozina,

D.V. Sokolova

et al.

Cardiometry, Journal Year: 2022, Volume and Issue: 24, P. 36 - 37

Published: Nov. 30, 2022

Molecules containing the N-acetylgalactosamine residue are capable to bind asialoglycoprotein receptor, a protein presented on surface of liver tumor cells; therefore it is suggested that doxorubicin conjugates such fragment can be delivered hepatocellular carcinoma cells as target, and then, upon hydrazone link splitting, in acidic environment release active substance.

Language: Английский

Citations

38
INFLUENCE OF HYPOTHYROIDISM ON THE HYPOTHALAMIC-PITUITARYGONADAL AXIS IN RATS WITH GUERIN'S TUMOR DOI Open Access

E.M. Frantsiyants,

V.A. Bandovkina,

I.V. Kaplieva

et al.

Cardiometry, Journal Year: 2022, Volume and Issue: 24, P. 48 - 49

Published: Nov. 30, 2022

The thyroid and the gonadal (HPG) regulatory axes are interconnected act together as a single system their imbalance leads to pathological responses of organism [1, 2]. involvement sex hormones in development malignant process has been discussed for many decades.

Language: Английский

Citations

38
Retroperitoneal Sarcoma Care in 2021 DOI Open Access
Erika Schmitz, Carolyn Nessim

Cancers, Journal Year: 2022, Volume and Issue: 14(5), P. 1293 - 1293

Published: March 2, 2022

Soft-tissue sarcomas are biologically heterogenous tumors arising from connective tissues with over 100 subtypes. Although account for <1% of all adult malignancies, retroperitoneal a distinct subgroup accounting <10% sarcomatous tumors. There have been considerable advancements in the understanding and treatment sarcoma last decade, standard consisting upfront primary surgical resection. The evidence surrounding addition radiation therapy remains controversial. no regards to systemic therapy, including immunotherapy. Adjunctive largely dictated by expert consensus preferences at individual centers or participation clinical trials. In this 2021 review, we detail anatomical boundaries retroperitoneum, characteristics, contemporary care well as recent care. Ongoing international collaborations encouraged advance our complex disease.

Language: Английский

Citations

34
Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness DOI Creative Commons
Myrofora Panagi,

Pampina Pilavaki,

Anastasia Constantinidou

et al.

Theranostics, Journal Year: 2022, Volume and Issue: 12(14), P. 6106 - 6129

Published: Jan. 1, 2022

Sarcomas are uncommon malignancies of mesenchymal origin that can arise throughout the human lifespan, at any part body.Surgery remains optimal treatment modality whilst response to conventional treatments, such as chemotherapy and radiation, is minimal.Immunotherapy has emerged a novel approach treat different cancer types but efficacy in soft tissue sarcoma bone limited distinct subtypes.Growing evidence shows cancer-stroma cell interactions their microenvironment play key role effectiveness immunotherapy.However, pathophysiological immunological properties tumor relation immunotherapy advances, not been broadly reviewed.Here, we provide an up-to-date overview modalities potential treatments for sarcoma, identify barriers posed by immunotherapy, highlight relevance impeding effectiveness, suggest mechanisms overcome these barriers.

Language: Английский

Citations

31
Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation? DOI Creative Commons
Chin Sern Yiong, Tzu Ping Lin, Vivian Lim

et al.

Biomarker Research, Journal Year: 2023, Volume and Issue: 11(1)

Published: Aug. 23, 2023

Abstract Sarcomas are a group of diverse and complex cancers mesenchymal origin that remains poorly understood. Recent developments in cancer immunotherapy have demonstrated potential for better outcomes with immune checkpoint inhibition some sarcomas compared to conventional chemotherapy. Immune inhibitors (ICIs) key agents immunotherapy, demonstrating improved many tumor types. However, most patients sarcoma do not benefit from treatment, highlighting the need identification development predictive biomarkers response ICIs. In this review, we first discuss United States (US) Food Drug Administration (FDA)-approved European Medicines Agency (EMA)-approved biomarkers, as well limitations their use sarcomas. We then review eight rationalize utility These include gene expression signatures (GES), circulating neutrophil-to-lymphocyte ratio (NLR), indoleamine 2,3-dioxygenase (IDO), lymphocyte activation 3 (LAG-3), T cell immunoglobin mucin domain-containing protein (TIM-3), TP53 mutation status, B cells, tertiary lymphoid structures (TLS). Finally, TLS both prognostic biomarker ICI be implemented clinic.

Language: Английский

Citations

18
Advancing rare cancer research by MALDI mass spectrometry imaging: Applications, challenges, and future perspectives in sarcoma DOI Creative Commons
Maren Nicole Stillger,

Mujia Li,

Pia Hönscheid

et al.

PROTEOMICS, Journal Year: 2024, Volume and Issue: 24(12-13)

Published: Feb. 25, 2024

Abstract MALDI mass spectrometry imaging (MALDI imaging) uniquely advances cancer research, by measuring spatial distribution of endogenous and exogenous molecules directly from tissue sections. These molecular maps provide valuable insights into basic translational including tumor biology, microenvironment, biomarker identification, drug treatment, patient stratification. Despite its advantages, is underutilized in studying rare cancers. Sarcomas, a group malignant mesenchymal tumors, pose unique challenges medical research due to their complex heterogeneity low incidence, resulting understudied subtypes with suboptimal management outcomes. In this review, we explore the applicability sarcoma showcasing value understanding highly heterogeneous challenging cancer. We summarize all studies date, highlight impact on key fields, signatures, heterogeneity, studies. address specific encountered when employing for sarcomas, propose solutions, such as using formalin‐fixed paraffin‐embedded tissues, multiplexed experiments, considerations multi‐site digital data sharing practices. Through aim spark collaboration between researchers clinical colleagues, deploy capabilities context sarcoma.

Language: Английский

Citations

7